{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:04:53Z","timestamp":1791295493392,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ijcard.2005.02.016","type":"journal-article","created":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T17:50:49Z","timestamp":1112896249000},"page":"367-372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":115,"title":["Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition"],"prefix":"10.1016","volume":"106","author":[{"given":"R.M.A.","family":"van de Wal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.M.","family":"Plokker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.A.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boomsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.L.","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"van Gilst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2005.02.016_bib1","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian enalapril survival study (CONSENSUS). The CONSENSUS trial study group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2005.02.016_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2005.02.016_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/00005344-198211000-00014","article-title":"Antihypertensive therapy with MK 421: angiotensin II\u2013renin relationships to evaluate efficacy of converting enzyme blockade","volume":"4","author":"Biollaz","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.HYP.16.5.564","article-title":"Determinants of angiotensin II generation during converting enzyme inhibition","volume":"16","author":"Juillerat","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2005.02.016_bib5","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/0002-9149(82)90390-3","article-title":"Increase in plasma aldosterone during prolonged captopril treatment","volume":"49","author":"Lijnen","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cardiores.2003.11.037","article-title":"Review of aldosterone- and angiotensin II-induced target organ damage and prevention","volume":"61","author":"Struthers","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijcard.2005.02.016_bib7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/hrt.75.6.576","article-title":"Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure","volume":"75","author":"Davidson","year":"1996","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2005.02.016_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.101.8.844","article-title":"Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure","volume":"101","author":"Jorde","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2005.02.016_bib9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/00004872-199410000-00008","article-title":"Angiotensin II formation by an alternative pathway during exercise in humans","volume":"12","author":"Miura","year":"1994","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2005.02.016_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","article-title":"How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?","volume":"82","author":"MacFadyen","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2005.02.016_bib11","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS trial study group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2005.02.016_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00050990","article-title":"Pathologic consequences of increased angiotensin II activity","volume":"10","author":"Ferrario","year":"1996","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ijcard.2005.02.016_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2005.02.016_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2005.02.016_bib15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2005.02.016_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/oxfordjournals.eurheartj.a015339","article-title":"The treatment of heart failure. Task force of the working group on heart failure of the European Society of Cardiology","volume":"18","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijcard.2005.02.016_bib17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.HYP.15.1.44","article-title":"Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension","volume":"15","author":"Admiraal","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2005.02.016_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0167-5273(00)00172-8","article-title":"Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones","volume":"73","author":"Teisman","year":"2000","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib19","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0735-1097(01)01237-2","article-title":"Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype","volume":"37","author":"Cicoira","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib20","doi-asserted-by":"crossref","first-page":"22348","DOI":"10.1016\/S0021-9258(18)45712-2","article-title":"Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart","volume":"265","author":"Urata","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijcard.2005.02.016_bib21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1042\/cs0600491","article-title":"Opposite effects of captopril on angiotensin I-converting enzyme \u2018activity\u2019 and \u2018concentration\u2019; relation between enzyme inhibition and long-term blood pressure response","volume":"60","author":"Boomsma","year":"1981","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ijcard.2005.02.016_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-8703(96)90558-X","article-title":"The role of neurohormonal activation in chronic heart failure and postmyocardial infarction","volume":"132","author":"Sigurdsson","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2005.02.016_bib23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1210\/endo.131.4.1396304","article-title":"Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells","volume":"131","author":"Geary","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.ijcard.2005.02.016_bib24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0002-9149(99)80748-6","article-title":"Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators","volume":"75","author":"Benedict","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/clpt.1986.95","article-title":"Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects","volume":"39","author":"Bussien","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijcard.2005.02.016_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2005.02.016_bib27","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","article-title":"Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy","volume":"40","author":"Rousseau","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijcard.2005.02.016_bib28","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2005.02.016_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527305004407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527305004407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:17:39Z","timestamp":1759090659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527305004407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0167527305004407"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2005.02.016","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2005.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}